VBI Vaccines (VBIV) Revenue & Revenue Breakdown
VBI Vaccines Revenue Highlights
Latest Revenue (Y)
$8.68M
Latest Revenue (Q)
$1.21M
Main Segment (Y)
Product
Main Geography (Y)
China Hong Kong
VBI Vaccines Revenue by Period
VBI Vaccines Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $8.68M | 702.40% |
| 2022-12-31 | $1.08M | 71.47% |
| 2021-12-31 | $631.00K | -40.53% |
| 2020-12-31 | $1.06M | -52.23% |
| 2019-12-31 | $2.22M | -33.80% |
| 2018-12-31 | $3.35M | 287.86% |
| 2017-12-31 | $865.00K | 57.85% |
| 2016-12-31 | $548.00K | -42.62% |
| 2015-12-31 | $955.00K | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-03-31 | - | 100.00% |
| 2007-03-31 | - | 100.00% |
| 2006-03-31 | - | 100.00% |
| 2005-03-31 | - | -100.00% |
| 2004-03-31 | $79.32 | -83.94% |
| 2003-03-31 | $493.94 | -2.86% |
| 2002-03-31 | $508.50 | 80614.29% |
| 2001-03-31 | $0.63 | -100.00% |
| 2000-03-31 | $68.84K | 3.89% |
| 1999-03-31 | $66.27K | -5.93% |
| 1998-03-31 | $70.45K | -2.79% |
| 1997-03-31 | $72.47K | - |
VBI Vaccines generated $8.68M in revenue during NA 2023, up 702.40% compared to the previous quarter, and up 258.78% compared to the same period a year ago.
VBI Vaccines Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $1.21M | 42.32% |
| 2023-12-31 | $853.00K | -87.12% |
| 2023-09-30 | $6.62M | 820.00% |
| 2023-06-30 | $720.00K | 48.45% |
| 2023-03-31 | $485.00K | 65.53% |
| 2022-12-31 | $293.00K | -7.57% |
| 2022-09-30 | $317.00K | -8.38% |
| 2022-06-30 | $346.00K | 174.60% |
| 2022-03-31 | $126.00K | 55.56% |
| 2021-12-31 | $81.00K | -24.30% |
| 2021-09-30 | $107.00K | -24.65% |
| 2021-06-30 | $142.00K | -52.82% |
| 2021-03-31 | $301.00K | 83.54% |
| 2020-12-31 | $164.00K | -44.97% |
| 2020-09-30 | $298.00K | 61.96% |
| 2020-06-30 | $184.00K | -55.66% |
| 2020-03-31 | $415.00K | -27.70% |
| 2019-12-31 | $574.00K | -11.28% |
| 2019-09-30 | $647.00K | 1.09% |
| 2019-06-30 | $640.00K | 77.78% |
| 2019-03-31 | $360.00K | -86.59% |
| 2018-12-31 | $2.68M | 936.29% |
| 2018-09-30 | $259.00K | 10.68% |
| 2018-06-30 | $234.00K | 31.46% |
| 2018-03-31 | $178.00K | -11.44% |
| 2017-12-31 | $201.00K | 4.15% |
| 2017-09-30 | $193.00K | -43.90% |
| 2017-06-30 | $344.00K | 170.87% |
| 2017-03-31 | $127.00K | -7.30% |
| 2016-12-31 | $137.00K | -51.25% |
| 2016-09-30 | $281.00K | 242.68% |
| 2016-06-30 | $82.00K | 70.83% |
| 2016-03-31 | $48.00K | -580.00% |
| 2015-12-31 | $-10.00K | -109.62% |
| 2015-09-30 | $104.00K | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-09-30 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | - |
VBI Vaccines generated $1.21M in revenue during Q1 2024, up 42.32% compared to the previous quarter, and up 414.33% compared to the same period a year ago.
VBI Vaccines Revenue Breakdown
VBI Vaccines Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Service | $3.99M | $151.00K | $369.00K | - | - |
| Product | $12.51M | $931.00K | $262.00K | - | - |
| License | $3.60M | - | - | - | - |
| R&D Services Revenue | - | - | - | $476.00K | - |
| Product Revenue | - | - | - | $8.69M | $536.00K |
| R&D Service Revenue | - | - | - | - | $1.69M |
VBI Vaccines's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (62.24%), Service (19.87%), and License (17.89%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service | $3.23M | $569.00K | $3.40M | $12.00K | $7.00K | $42.00K | $59.00K | $15.00K | $35.00K | $81.00K | $83.00K | $71.00K | $134.00K | $94.00K | $283.00K | $166.00K | - | - | - | - |
| Product | $5.49M | $6.01M | $5.31M | $708.00K | $478.00K | $251.00K | $258.00K | $331.00K | $91.00K | - | $24.00K | $71.00K | $167.00K | $70.00K | $15.00K | $18.00K | - | - | - | - |
| License | $2.50M | - | $3.60M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product Revenues | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $180.00K | $168.00K | $104.00K | - |
| R&D Service Revenues | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $235.00K | $479.00K | $536.00K | - |
| R&D Service Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $403.00K | - | - |
| Product Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $171.00K | - | - |
VBI Vaccines's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (48.94%), Service (28.80%), and License (22.27%).
VBI Vaccines Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| ISRAEL | $167.00K | $315.00K | $321.00K | $284.00K | - |
| UNITED STATES | $1.84M | $695.00K | - | - | - |
| China Hong Kong | $5.58M | - | - | - | - |
| Europe | $1.08M | $6.00K | $4.00K | $53.00K | $131.00K |
| China / Hong Kong | - | $66.00K | $306.00K | $724.00K | - |
| Israel | - | - | - | - | $455.00K |
| China/Hong Kong | - | - | - | - | $1.64M |
VBI Vaccines's latest annual revenue breakdown by geography, as of Dec 23: China Hong Kong (64.33%), UNITED STATES (21.25%), Europe (12.50%), and ISRAEL (1.92%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China and Hong Kong | $32.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| UNITED STATES | $961.00K | $325.00K | $690.00K | $508.00K | $322.00K | $251.00K | $238.00K | $207.00K | - | - | - | - | - | - | - | - | - | - | - | - |
| ISRAEL | $20.00K | $68.00K | $42.00K | $57.00K | $34.00K | $60.00K | $126.00K | $95.00K | $21.00K | $44.00K | $87.00K | $169.00K | $86.00K | $48.00K | $19.00K | - | - | - | - | - |
| Europe | $201.00K | $455.00K | $330.00K | $144.00K | $156.00K | - | $6.00K | - | $4.00K | - | - | $52.00K | $16.00K | $46.00K | $69.00K | - | - | - | - | - |
| China Hong Kong | - | $12.00K | $5.56M | $11.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China / Hong Kong | - | - | - | - | $7.00K | $8.00K | $25.00K | $60.00K | $55.00K | $128.00K | $78.00K | $250.00K | $231.00K | - | - | - | - | - | - | - |
| CANADA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| CHINA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $165.00K | - | - | - | - |
| Israel | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $132.00K | $168.00K | $134.00K | $54.00K |
| China/Hong Kong | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $390.00K | $467.00K | $517.00K |
VBI Vaccines's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (79.16%), Europe (16.56%), China and Hong Kong (2.64%), and ISRAEL (1.65%).
VBI Vaccines Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ONTX | Traws Pharma | $226.00B | $56.00K |
| AUPH | Aurinia Pharmaceuticals | $158.53M | $55.03M |
| ARDX | Ardelyx | $124.46M | $73.22M |
| GRTS | Gritstone bio | $16.34M | $49.00K |
| JAGX | Jaguar Health | $9.76M | $2.72M |
| BBIO | BridgeBio Pharma | $9.30M | $2.17M |
| VBIV | VBI Vaccines | $8.68M | $1.21M |
| TNXP | Tonix Pharmaceuticals | $7.77M | $2.21M |
| VXRT | Vaxart | $7.38M | $6.40M |
| OCGN | Ocugen | $6.04M | $1.14M |
| ANIX | Anixa Biosciences | $210.00K | - |
| ALLO | Allogene Therapeutics | $95.00K | $22.00K |
| GOVX | GeoVax Labs | - | - |
| ANVS | Annovis Bio | - | - |
| AKRO | Akero Therapeutics | - | - |
VBIV Revenue FAQ
What is VBI Vaccines’s yearly revenue?
VBI Vaccines's yearly revenue for 2023 was $8.68M, representing an increase of 702.40% compared to 2022. The company's yearly revenue for 2022 was $1.08M, representing an increase of 71.47% compared to 2021. VBIV's yearly revenue for 2021 was $631K, representing a decrease of -40.53% compared to 2020.
What is VBI Vaccines’s quarterly revenue?
VBI Vaccines's quarterly revenue for Q1 2024 was $1.21M, a 42.32% increase from the previous quarter (Q4 2023), and a 150.31% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $853K, a -87.12% decrease from the previous quarter (Q3 2023), and a 191.13% increase year-over-year (Q4 2022). VBIV's quarterly revenue for Q3 2023 was $6.62M, a 820.00% increase from the previous quarter (Q2 2023), and a 1989.59% increase year-over-year (Q3 2022).
What is VBI Vaccines’s revenue growth rate?
VBI Vaccines's revenue growth rate for the last 3 years (2021-2023) was 1275.91%, and for the last 5 years (2019-2023) was 290.90%.
What are VBI Vaccines’s revenue streams?
VBI Vaccines's revenue streams in c 23 are Service, Product, and License. Service generated $3.99M in revenue, accounting 19.87% of the company's total revenue, up 2543.71% year-over-year. Product generated $12.51M in revenue, accounting 62.24% of the company's total revenue, up 1243.39% year-over-year. License generated $3.6M in revenue, accounting 17.89% of the company's total revenue
What is VBI Vaccines’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of VBI Vaccines was Product. This segment made a revenue of $12.51M, representing 62.24% of the company's total revenue.